• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    test company saurabh

    Emergent BioSolutions

    Reed-Lane

    PCI Pharma Services

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Alcami

    test company saurabh

    Baxter BioPharma Solutions

    PCI Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Flexible Manufacturing Strategies and Data Integrity

    Making processes integral with your data handling ability

    Flexible Manufacturing Strategies and Data Integrity
    Related CONTENT
    • Solid Dose Market Trends
    • High Purity New England Bolsters Biopharma Solutions Services
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • ACG Launches ACG Laboratories
    • Catalent Acquires Delphi Genetics
    Emil W. Ciurczak, DoraMaxx Consulting11.07.17
    In this article, I will review two topics that are integral in a modern pharmaceutical process: flexible manufacturing and the manner in which we store, protect, use, and retrieve all our data—and apply these data to controlling the process. The word flexible may sound exciting, new, and modern—and it is all those things. However, the flip side of flexible is complexity. Complexity of hardware and complexity of the data streaming off the equipment, and the complexity of the algorithms needed to control the process.

    However, before we address these topics in detail, we need to understand how much hardware and software is needed to co-develop since the “good, old days.” Back in the early 1980s, I was thrilled to be able to use an early version of HPLC integrating software, which made my life easier. However, the version we had on our LIMS (lab management information system) was written by computer experts who had no idea of what chromatography was. In this version, the cursor needed to be manually placed at the beginning and end of each peak to be analyzed. One PIXEL off the baseline and the system might integrate all the peaks as one and you could easily get a 500% assay or higher. This “tiny” flaw allowed each person to choose the area of each peak as he or she saw it, which could lead to errors or, gasp, the ability to fake data. As chemists were included in the software writing team, the results became both more accurate and more reproducible.

    Clearly, primitive computer programs in the 1980s could neither monitor nor control any normal, batch-wise process, much less a complex, flexible system, which could easily be reconfigured daily. Add to that the simple, non-memory-capable computers available at that time and we have a “Leonardo da Vinci” scenario. I refer to the fact that Maestro Leonardo designed an airplane, centuries before an internal combustion engine was built. He also designed a computer, centuries before integrated circuits were built, but I digress. Computers in the 1980s didn’t even have memories; the one I was working with—NIR program—was equipped with an external 9-megabyte hard drive yet, bigger than our lab’s LIBS computer storage at that time. For comparison, a typical smart-phone has many times the capacity and speed of 35-year old computers.

    Back to the crux of this article. The first half of the computer/process equation is based on good engineering and knowledge of the product line. Here’s where PAT and QbD rear their dual heads. The second half is based on excellent algorithms, hardware, and interfaces with the hardware. In truth, the production hardware fails miserably without the software. With over 2.5 million terabytes of data being created by the Pharma industry every day, the task is obviously not trivial. But, ignoring the massive amounts of data and the ability to crunch and store it, all those “0s” and “1s” mean nothing if they are used on a process based on 50-year old practices and “common knowledge.”

    Remember, in the dim past when the first food and drug acts were published, there were few large commercial Pharma plants out there. Where they existed, 100,000 tablets or capsules were considered huge lots. A majority of medicinal products were still being concocted in the back rooms of your local pharmacist. Formulations were pretty much like your mom’s recipe for apple pie: peculiar to each pharmacist and his assistants. Since a patient was unlikely to use more than his/her neighborhood pharmacy, differences didn’t matter.

    When the FDA was created to assure safety—only a second passage of the law added “efficacy” of the product as a requirement—of drugs, the government, in its wisdom, appointed an MD to head the agency. In turn, the head of the FDA turned to the people he was familiar with and stated that commercial production should be overseen by pharmacists. Now, the fact that a pharmacy degree at the time was a two-year curriculum with little to no inclusion of commercial hardware apparently didn’t factor into the decision. A typical school of pharmacy now grants degrees from five-year programs and most schools have sophisticated production equipment upon which they practice.

    While there was a fair amount of carry-over from the back rooms of a pharmacy to small commercial lots made at a single facility, the paradigm was not built to handle more than a million lots, manufactured at multiple locations, in multiple process lines. In fact, statistically taking 20-30 dosage forms out of dozens of drums for assay is difficult and may not be done. And, even assuming that the samples sent to the lab are representative, two other minor facts need to be addressed:
    1. The tests are decades out of date and may or may not show more than the ones being assayed contain the allowed levels of API. The other “tests,” such as dissolution, hardness, weight variation, etc., give us data to fill in the blanks on the Master Manufacturing Formula (MMF). However, remember, data is not always information.
    2. However good or bad these tests may be, they cannot actually affect the outcome of the lot being assayed. After-the-fact analyses can only tell the company to sell or destroy an already completed batch. It’s not too expensive with a 100,000-tablet lot, but 5,000,000 tablets? Now that’s another story. Additionally, the fact that a process was Out-of-Specification (OOS) is all that is determined, not where it went wrong of how and when it could have been corrected to avoid a failing batch.
    So, back to the idea of computers and process knowledge co-evolving. With the advent of the U.S. FDA’s PAT Guidance, companies are finding several things to be true:
    1. They didn’t know as much about the physics of their process as they thought. Yes, physics and physical chemistry. The “traditional” chemistry is all in the synthesis of the API, which today, is seldom done in-house, anymore.
    2. They needed to expand their personnel repertoire. Aside for the traditional formulators (pharmacists), they were beginning to recognize the need to ether hire or consult with material scientists, process engineers, statisticians, Chemometricians, and so forth.
    3. The analytical tests they had long depended upon to assure a quality product were either not giving the answers they thought they were, were not timely—not fit for controlling a process—or both.
    4. They needed new technologies, skills, and a way to gather, crunch, and utilize the mounds of data generated by these new technologies. For example, a spectrometer can generate a new spectrum every few milliseconds, with its throttle wide open.
    5. They also needed computers and skilled operators and programmers. Obviously, the computers are “store-bought.” The operators of the computers may be hired or the skills taught to existing professionals, but few companies start out with either the people or the experience to install the monitoring/controlling systems on day one. So, more people and/or outside experts are needed.
    So, this new data, generated by PAT/QbD-controlled processes, great as it might be, will increase rapidly, need to be handled more rapidly, need to be nimble and simple to change-over between process runs, and be 21CFR part 11 compliant. No biggie, huh? Fortunately, nature abhors a vacuum, so there are specialty companies popping up on every continent, offering their services. But, as with any technology you purchase, you need to perform due diligence. Were it a car, you need to do more than “kick the tires.” Why anyone does that is beyond me. Anyway, be critical is my message.

    Before you entrust your livelihood to a new technology, walk before you run. My approach would be to become familiar with the terms and tools of PAT, first. Attend meetings, read the literature, chat with peers, and yes, even invest in a consultant or two. I would strongly suggest attempting some of the oldest and most successful PAT steps, as a first step. Set up a raw materials program, using NIRS or Raman. The information gleaned from this will help both formulators and production staff. Simultaneously, work with your IT department to store and retrieve the spectra and data generated from this program.

    When you are feeling confident in your ability to generate and crunch data (Chemometrically), show that any or all information may be called up for an Agency inspector, and have expanded your storage capacity for the onslaught of terabytes of data to come. Then you are ready for steps two through  “n.”

    The second step in your process stream I would tackle is blending. All you have to do is try to mix cinnamon and sugar at home to show you may not have the knowledge to do it easily. In production, we still rely on the three demo batches as a guide, never making changes, based on materials information—gleaned from the first step above. By placing a NIR or LIF monitor on your blender, and controlling it with your brand spanking new computer system, you now will always achieve perfect blends. Expand this to granulating, tableting, coating, and even packaging and you will cut your OOS lots to near zero.

    All of this is based on the belief that your generated data is both easily retrieved and secure. Why secure? Recent instances of cybercrime show that hackers can get into almost any system, any time they wish. In the case of a generic manufacturer, unless you are simply copying an existing, marketed product, your formulation information is your marketing edge and you do not want to share it. For a contract manufacturing organization (CMO) generating a product for an originator, you also do not want the formulation and process parameters to become general knowledge.

    So, the bottom line is make your process integral with your data handling ability. See? IT is now part of Production. Expand and modernize, but work just as hard to secure the data as you did to generate and store it.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • it
    • fda
    • API
    • flexible manufacturing
    Suggested For You
    Solid Dose Market Trends Solid Dose Market Trends
    High Purity New England Bolsters Biopharma Solutions Services High Purity New England Bolsters Biopharma Solutions Services
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    Catalent Acquires Delphi Genetics Catalent Acquires Delphi Genetics
    Vetter continues its successful performance at the 2021 CMO Leadership Awards Vetter continues its successful performance at the 2021 CMO Leadership Awards
    NovalGen and Halix Enter Strategic Partnership NovalGen and Halix Enter Strategic Partnership
    MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement MaxiVAX, Minaris Enter Cell Therapy Mfg. Agreement
    G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing G-CON Manufacturing Delivers & Installs PODs for Cell Therapy Manufacturing
    Intravacc Unveils New Pilot Vaccine Production Facility Intravacc Unveils New Pilot Vaccine Production Facility
    Pfizer, BioNTech To Supply 200M More Vax Doses to EU Pfizer, BioNTech To Supply 200M More Vax Doses to EU
    Lonza Expands Solid Small Molecule Services Lonza Expands Solid Small Molecule Services
    Scapa Healthcare Enhances OTC Drug Manufacturing Capabilities Scapa Healthcare Enhances OTC Drug Manufacturing Capabilities
    LipoMedix, ForDoz Enter Manufacturing Agreement LipoMedix, ForDoz Enter Manufacturing Agreement
    RotaChrom Technologies Partners with Cyclolab RotaChrom Technologies Partners with Cyclolab

    Related Columns

    • Information Technology
      Probing the Limits of Pharma’s Future

      Probing the Limits of Pharma’s Future

      A retrospective on the past 20 years and a prospective on where the future will take us.
      Ben Locwin, Contributing Writer 10.15.19

    • Drug Discovery | Information Technology
      Artificial Intelligence and Machine Learning in Healthcare

      Artificial Intelligence and Machine Learning in Healthcare

      Because your summertime reading should make you a little uncomfortable.
      Ben Locwin, PhD, MBA, MS, Contributing Editor 07.15.19

    • Information Technology
      My Head is in The Cloud(s)

      My Head is in The Cloud(s)

      Cloud computing is making it easier to control all aspects of the global pharma production process
      Emil W. Ciurczak, DoraMaxx Consulting 05.07.19


    • Information Technology
      Putting Data Integrity in Quality Agreements

      Putting Data Integrity in Quality Agreements

      With growing regulatory scrutiny, sponsors are focusing more on data integrity in supplier quality agreements.
      Robert Marohn, ClinLogic, LLC 06.12.18

    • Information Technology
      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA

      New GXP Data Integrity Guidance Published by MHRA
      Robert Marohn, ClinLogic, LLC 04.10.18

    • APIs | Information Technology
      India’s Pharmaceutical Industry Outlook

      India’s Pharmaceutical Industry Outlook

      Market predicted to be worth $50B by 2020
      Dr. Gurpreet Sandhu, Reva Pharmachem 03.06.15


    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • ICON Acquires Medpass
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login